Intensifying Induction Therapy in Acute Myeloid Leukemia: Has a New Standard of Care Emerged?

This publication has 62 references indexed in Scilit:

• Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin
  Nature, 1994
• Idarubicin is active on MDR cells: evaluation of DNA synthesis inhibition on P388 cell lines
  Annals of Hematology, 1993
• Cytotoxicity of adriamycin, idarubicin, and vincristine in acute myeloid leukemia: Chemosensitization by verapamil in relation to P-glycoprotein expression
  Annals of Hematology, 1992
• Comparative pharmacokinetic study of idarubicin and daunorubicin in leukemia patients
  Hematological Oncology, 1992
• A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia
  European Journal of Cancer and Clinical Oncology, 1991
• Long-term outcome of adults with acute myelogenous leukaemia: results of a prospective, randomized study of chemotherapy with a minimal follow-up of 7 years
  British Journal of Haematology, 1991
• The frequency of long‐term remission in patients with acute myelogenous leukaemia treated with conventional maintenance chemotherapy: a study of 760 patients with a minimal follow‐up time of 6 years
  British Journal of Haematology, 1989
• Treatment of acute myeloid leukemia in elderly patients.A retrospective study
  Cancer, 1988
• A comparative trial of daunorubicin, cytosine arabinoside, and thioguanine, and a combination of the three agents for the treatment of acute myelocytic leukemia
  Medical and Pediatric Oncology, 1979
• Daunomycin, cytosine arabinoside and 6-thioguanine (DAT) vs vincristine, cytosine arabinoside and 6-thioguanine (VAT) in the induction treatment of acute nonlymphocytic leukemia: A randomized collaborative study
  Medical and Pediatric Oncology, 1978